Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Published:2021-04 Issue:4 Volume:43 Page:684-700
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Nasser Azmi,Liranso Tesfaye,Adewole Toyin,Fry Nicholas,Hull Joseph T.^ORCID,Chowdhry Fatima,Busse Gregory D.,Melyan Zare,Cutler Andrew J.,Findling Robert L.,Schwabe Stefan

Funder

Supernus Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference57 articles.

1. Diagnostic and Statistical Manual of Mental Disorders,2013

2. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients;Adesman;Prim Care Companion J Clin Psychiatr,2001

3. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity;Sibley;J Child Psychol Psychiatr,2017

4. Pharmacologic treatment of attention deficit-hyperactivity disorder;Cortese;N Engl J Med,2020

5. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment;Shaw;BMC Med,2012

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mood Disorders with Attention-Deficit/Hyperactivity Disorder, Impulse Control Disorders, or Borderline Personality Disorder;Clinical Textbook of Mood Disorders;2024-05-30

2. The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium;Expert Opinion on Pharmacotherapy;2024-05-23

3. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants;Expert Opinion on Pharmacotherapy;2024-05-02

4. VILOXAZINE;Prescriber's Guide – Children and Adolescents;2024-05-02

5. From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care;Journal of Child and Adolescent Psychopharmacology;2024-05-01